Stay updated with breaking news from Scottd Barnes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In March 2022, the U.S. Food and Drug Administration (FDA) granted approval of the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the correction of myopia and myopia with astigmatism. Myopia is also known as nearsightedness or the need for distance vision correction.
LAKE FOREST, Calif.--(BUSINESS WIRE)--Mar 28, 2022--
Staar Surgical (Nasdaq:STAA) announced today that it received FDA approval for its Evo/Evo+ Visian implantable Collamer lens.
The FDA approved the EVO/EVO+ Visian implantable Collamer lens for the correction of myopia and myopia with astigmatism, according to a press release from STAAR Surgical.The EVO lenses are implanted in the posterior chamber, behind the iris and in front of the patient’s natural crystalline lens. A preoperative peripheral iridotomy, which was required with earlier versions of the Visian ICL,